MAPT and Alzheimer disease: Furthermore, in vivo mouse models of AD (Tg Tau P301S mice) showed reduced levels of phospho-tau (p-tau) and total tau (t-tau) after SYK inhibition with BAY61-3606 (20 mg/kg) over a course of 12 weeks [26].